Triptorelin
Aliases: Decapeptyl · Trelstar · Gonapeptyl
Last verified: 2026-09-23
The short version
A depot GnRH agonist — same indications as leuprolide; also known for (imprudent) micro-dose "PCT restart" use in fitness circles.
Identity & type
- Molecular type
- analog
- Origin
- A depot GnRH agonist — same indications as leuprolide; also known for (imprudent) micro-dose "PCT restart" use in fitness circles.
Mechanism of action
GnRHR agonism → desensitization; micro-doses give an acute LH/FSH spike.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. Depot 3.75–22.5 mg; "PCT" micro-dose ~100 mcg once (off-label, risky).
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Depot 3.75–22.5 mg; "PCT" micro-dose ~100 mcg once (off-label, risky). Similar to leuprolide; stable hormonal suppression in patients with 1–6-month depot formulations.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Similar to leuprolide; stable hormonal suppression in patients with 1–6-month depot formulations.
Protocol — official vs community
Official / label
Trelstar / Decapeptyl and generics, depot IM: 3.75 mg monthly, 11.25 mg q3-month or 22.5 mg q6-month for advanced prostate cancer; other markets approve precocious puberty and assisted-reproduction scheduling.
- 01Formulation interval (1/3/6-month depots) selected per indication and duration of therapy
Duration: Months to years per indication, mirroring leuprolide.
Same pharmacology as leuprolide — superactive GnRH agonism with an initial flare before pituitary desensitization. The three depot strengths give the same suppression with different visit cadence.
Community (anecdotal)
A recurring fitness-community practice: a single ~100 mcg subcutaneous 'micro-dose' framed as a one-shot PCT/HPTA restart after anabolic-steroid cycles.
- Cycle:
- Single dose, sometimes repeated — which is precisely the problem.
- Break:
- —
This is the one compound where the compounds.json entry itself flags the practice as imprudent: a GnRH agonist's acute effect is stimulation of LH/FSH, and repeated dosing flips into long-term pituitary desensitization. The 'one micro-dose restart' sits awkwardly between those two regimes and has no clinical evidence behind it.
Human evidence
Approved standard; off-label use undocumented.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Depot: suppression; micro-dose: risk of lasting desensitization if repeated.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials